Company / Operating Cash Flow per Share
Axsome Therapeutics, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$1.92
FY2025
5-year range
-$3.34 / -$1.92
FY2021-FY2025
Trend
+29.2%
vs FY2024
Sector context
#145 of 212
Health Care
What the data says
At $-1.92, Axsome Therapeutics, Inc.'s operating cash flow per share ranks #145 of 212 in the Health Care sector. Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-3.34 in FY2023 to $-1.11 in FY2016.
Based on SEC 10-K filings.
-1.92 in FY2025.
Improved from $-3.34 to $-1.92 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#145 of 212 in Health CareTop 68% of 212This company -$1.92 Sector average -$14.72
▼
+87.0% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 29.2% year-over-year.
- Ranks #145 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2016.
- Lowest operating cash flow per share in the period was in FY2023.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.92 | +29.2% |
| FY2024 | -$2.71 | +18.7% |
| FY2023 | -$3.34 | -8.3% |
| FY2022 | -$3.08 | -7.1% |
| FY2021 | -$2.88 | -36.4% |
| FY2020 | -$2.11 | -54.7% |
| FY2019 | -$1.36 | -21.9% |
| FY2018 | -$1.12 | +3.9% |
| FY2017 | -$1.16 | -4.6% |
| FY2016 | -$1.11 | -78.4% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026